{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:27:29Z","timestamp":1773455249569,"version":"3.50.1"},"reference-count":123,"publisher":"Scientific Scholar","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol Venereol Leprol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/ijdvl.ijdvl_991_16","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T12:44:52Z","timestamp":1513773892000},"page":"6","source":"Crossref","is-referenced-by-count":4,"title":["Antihypertensives in dermatology Part I - Uses of antihypertensives in dermatology"],"prefix":"10.25259","volume":"84","author":[{"given":"P. S. S.","family":"Ranugha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JayadevB","family":"Betkerur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0378-6323.221316-1","unstructured":"Piascik MT. The Therapy of Hypertension. PHA 824. University of Kentucky. Available from: http:\/\/www.uky.edu\/~mtp\/hypertension_08.htm. [Last cited on 2017 Apr 20]."},{"key":"key-10.4103\/0378-6323.221316-2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.det.2012.08.003","article-title":"Pattern hair loss in men: Diagnosis and medical treatment","author":"Banka","year":"2013","journal-title":"Dermatol Clin"},{"key":"key-10.4103\/0378-6323.221316-3","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.221316-4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1610-0379.2011.07802.x","article-title":"Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men","author":"Blumeyer","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"key-10.4103\/0378-6323.221316-5","first-page":"1594","article-title":"Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: Possible involvement of sulfonylurea receptor 2B as a target of minoxidil","author":"Li","year":"2001","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/0378-6323.221316-6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jsps.2012.11.005","article-title":"Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia","author":"Uprit","year":"2013","journal-title":"Saudi Pharm J"},{"key":"key-10.4103\/0378-6323.221316-7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3109\/02652048.2011.604435","article-title":"Chitosan microparticles for sustaining the topical delivery of minoxidil sulphate","author":"Gelfuso","year":"2011","journal-title":"J Microencapsul"},{"key":"key-10.4103\/0378-6323.221316-8","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/jps.23485","article-title":"Iontophoresistargeted, follicular delivery of minoxidil sulfate for the treatment of alopecia","author":"Gelfuso","year":"2013","journal-title":"J Pharm Sci"},{"key":"key-10.4103\/0378-6323.221316-9","doi-asserted-by":"crossref","unstructured":"Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 2011;65:1126-34.e2.","DOI":"10.1016\/j.jaad.2010.09.724"},{"key":"key-10.4103\/0378-6323.221316-10","first-page":"5","article-title":"5% Minoxidil: Treatment for female pattern hair loss","author":"Gupta","year":"2014","journal-title":"Skin Therapy Lett"},{"key":"key-10.4103\/0378-6323.221316-11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1067\/mjd.2002.124088","article-title":"Arandomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men","author":"Olsen","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0190-9622(90)70089-Z","article-title":"Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil","author":"Olsen","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0190-9622(99)70006-X","article-title":"Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment","author":"Price","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/dth.12111","article-title":"Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia","author":"Goren","year":"2014","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/0378-6323.221316-15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-2133.2003.05435.x","article-title":"The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: A randomized controlled trial","author":"Berger","year":"2003","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.221316-16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00128071-200708050-00003","article-title":"Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: A randomized, double-blind, comparative clinical trial","author":"Shin","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"key-10.4103\/0378-6323.221316-17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0190-9622(87)80003-8","article-title":"Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata","author":"Fiedler-Weiss","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archderm.1990.01670300056006","article-title":"Treatment-resistant alopecia areata.Response to combination therapy with minoxidil plus anthralin","author":"Fiedler","year":"1990","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0378-6323.221316-19","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0190-9622(87)70095-4","article-title":"Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata","author":"Price","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1523-1747.ep12611409","article-title":"Topical minoxidil in alopecia areata: No effect on the perifollicular lymphoid infiltration","author":"Khoury","year":"1992","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/0378-6323.221316-21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-4632.2009.03907.x","article-title":"Alopecia in congenital hidrotic ectodermal dysplasia responding to treatment with a combination of topical minoxidil and tretinoin","author":"Melkote","year":"2009","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0378-6323.221316-22","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jaad.2012.10.019","article-title":"Topical minoxidil treatment for congenital alopecia in hypohidrotic ectodermal dysplasia","author":"Lee","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5021\/ad.2013.25.3.387","article-title":"Successful treatment of temporal triangular alopecia with topical minoxidil","author":"Bang","year":"2013","journal-title":"Ann Dermatol"},{"key":"key-10.4103\/0378-6323.221316-24","first-page":"894","article-title":"The potential role of minoxidil in the hair transplantation setting","author":"Avram","year":"2002","journal-title":"Dermatol Surg"},{"key":"key-10.4103\/0378-6323.221316-25","first-page":"23","article-title":"The potential role of minoxidil in the hair transplantation setting","author":"Singh","year":"1998","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.221316-26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1529-8019.2011.01430.x","article-title":"Treatment of chemotherapy-induced alopecia","author":"Yeager","year":"2011","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/0378-6323.221316-27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","article-title":"Arandomized trial of minoxidil in chemotherapy-induced alopecia","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10227-002-0121-6","article-title":"Safety of topical minoxidil solution: A one-year, prospective, observational study","author":"Shapiro","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"key-10.4103\/0378-6323.221316-29","first-page":"271","article-title":"Hypertrichosis in females applying minoxidil topical solution and in norma controls.J Eur Acad Dermatol Venereol","author":"Dawber","year":"2003","journal-title":""},{"key":"key-10.4103\/0378-6323.221316-30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-4632.2011.04890.x","article-title":"Erosive pustular dermatosis of the scalp from topical minoxidil 5% solution","author":"Guarneri","year":"2013","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0378-6323.221316-31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/15569527.2011.613427","article-title":"Central chorioretinopathy associated with topical use of minoxidil 2% for treatment of baldness","author":"Scarinci","year":"2012","journal-title":"Cutan Ocul Toxicol"},{"key":"key-10.4103\/0378-6323.221316-32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/PRS.0b013e31827c6fab","article-title":"Propranolol versus corticosteroids in the treatment of infantile hemangioma: A systematic review and meta-analysis","author":"Izadpanah","year":"2013","journal-title":"Plast Reconstr Surg"},{"key":"key-10.4103\/0378-6323.221316-33","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/archdischild-2014-306514","article-title":"Propranolol for infantile haemangiomas: Single centre experience of 250 cases and proposed therapeutic protocol","author":"Solman","year":"2014","journal-title":"Arch Dis Child"},{"key":"key-10.4103\/0378-6323.221316-34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/120347541201600508","article-title":"Propranolol in the treatment of problematic infantile hemangioma: Review of 35 consecutive patients from a vascular anomalies clinic","author":"Bertrand","year":"2012","journal-title":"J Cutan Med Surg"},{"key":"key-10.4103\/0378-6323.221316-35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13312-013-0098-9","article-title":"Propranolol therapy for infantile hemangioma","author":"Gunturi","year":"2013","journal-title":"Indian Pediatr"},{"key":"key-10.4103\/0378-6323.221316-36","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1097\/MPH.0b013e3182152e4e","article-title":"Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: A new indication for propranolol treatment","author":"Hermans","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"key-10.4103\/0378-6323.221316-37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/0971-9261.91086","article-title":"Kasabach-Merritt syndrome with large cutaneous vascular tumors","author":"Arunachalam","year":"2012","journal-title":"J Indian Assoc Pediatr Surg","ISSN":"https:\/\/id.crossref.org\/issn\/0971-9261","issn-type":"print"},{"key":"key-10.4103\/0378-6323.221316-38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2133.2010.09848.x","article-title":"Propranolol for infantile haemangiomas: Insights into the molecular mechanisms of action","author":"Storch","year":"2010","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.221316-39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.0.CO;2-V","article-title":"cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation","author":"D'Angelo","year":"1997","journal-title":"J Cell Biochem"},{"key":"key-10.4103\/0378-6323.221316-40","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.jpedsurg.2012.09.008","article-title":"Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells","author":"Ji","year":"2012","journal-title":"J Pediatr Surg"},{"key":"key-10.4103\/0378-6323.221316-41","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/PRS.0b013e318267d3db","article-title":"Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells","author":"Wong","year":"2012","journal-title":"Plast Reconstr Surg"},{"key":"key-10.4103\/0378-6323.221316-42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00431-013-2105-5","article-title":"Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure","author":"McSwiney","year":"2014","journal-title":"Eur J Pediatr"},{"key":"key-10.4103\/0378-6323.221316-43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1542\/peds.2012-1691","article-title":"Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference","author":"Drolet","year":"2013","journal-title":"Pediatrics"},{"key":"key-10.4103\/0378-6323.221316-44","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/pde.12972","article-title":"Is routine electrocardiography necessary before initiation of propranolol for treatment of infantile hemangiomas?","author":"Yarbrough","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"key-10.4103\/0378-6323.221316-45","first-page":"e423\u201331","article-title":"Propranolol for severe infantile hemangiomas: A follow-up report.Pediatrics","author":"Sans","year":"2009","journal-title":""},{"key":"key-10.4103\/0378-6323.221316-46","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/pde.12089","article-title":"Propranolol and infantile hemangiomas four years later: A systematic review","author":"Marqueling","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"key-10.4103\/0378-6323.221316-47","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/pde.12190","article-title":"Late rebound of infantile hemangioma after cessation of oral propranolol","author":"Shehata","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"key-10.4103\/0378-6323.221316-48","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1542\/peds.2010-0029","article-title":"A randomized controlled trial of propranolol for infantile hemangiomas","author":"Hogeling","year":"2011","journal-title":"Pediatrics"},{"key":"key-10.4103\/0378-6323.221316-49","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cod.12248","article-title":"Allergic contact dermatitis caused by topical propranolol in a 5-month-old baby","author":"Bonifazi","year":"2014","journal-title":"Contact Dermatitis"},{"key":"key-10.4103\/0378-6323.221316-50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjd.13379","article-title":"Propranolol and central nervous system function: Potential implications for paediatric patients with infantile haemangiomas","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.221316-51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jaad.2015.04.053","article-title":"Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development","author":"Moyakine","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-52","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/bjd.12432","article-title":"Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol","author":"Ahogo","year":"2013","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.221316-53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/pde.12239","article-title":"Long-term treatment with oral propranolol reduces relapses of infantile hemangiomas","author":"Giachetti","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"key-10.4103\/0378-6323.221316-54","doi-asserted-by":"crossref","first-page":"e1739","DOI":"10.1542\/peds.2012-3828","article-title":"RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds","author":"Chan","year":"2013","journal-title":"Pediatrics"},{"key":"key-10.4103\/0378-6323.221316-55","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/pde.12209","article-title":"Topical timolol 0.5% gel-forming solution for small deep facial infantile hemangiomas","author":"Sorrell","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"key-10.4103\/0378-6323.221316-56","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/SAP.0000000000000390","article-title":"Local administration of \u00df-blockers for infantile hemangiomas: A systematic review and meta-analysis","author":"Ovadia","year":"2015","journal-title":"Ann Plast Surg"},{"key":"key-10.4103\/0378-6323.221316-57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2015.09.061","article-title":"Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial","author":"Zaher","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","article-title":"Calcium channel blockers for primary Raynaud's phenomenon: A meta-analysis","author":"Thompson","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"key-10.4103\/0378-6323.221316-59","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","article-title":"Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.221316-60","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon.A randomized, controlled study","author":"Scorza","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"key-10.4103\/0378-6323.221316-61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/VHRM.S5255","article-title":"Recent achievements in the management of Raynaud's phenomenon","author":"Baumh\u00e4kel","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"key-10.4103\/0378-6323.221316-62","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2165\/00003495-200767040-00003","article-title":"The diagnosis and treatment of Raynaud's phenomenon: A practical approach","author":"Pope","year":"2007","journal-title":"Drugs"},{"key":"key-10.4103\/0378-6323.221316-63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/j.1552-4604.1982.tb05712.x","article-title":"The treatment of severe Raynaud's phenomenon with verapamil","author":"Kinney","year":"1982","journal-title":"J Clin Pharmacol"},{"key":"key-10.4103\/0378-6323.221316-64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard.44.1.30","article-title":"A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon","author":"Kahan","year":"1985","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0378-6323.221316-65","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/000331978503601203","article-title":"Effects of diltiazem on occupational Raynaud's syndrome (vibration disease)","author":"Matoba","year":"1985","journal-title":"Angiology"},{"key":"key-10.4103\/0378-6323.221316-66","first-page":"858","article-title":"Inefficacy of diltiazem in the treatment of Raynaud's phenomenon with associated connective tissue disease: A double blind placebo controlled study","author":"da","year":"1987","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.221316-67","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","article-title":"Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon","author":"Teh","year":"1995","journal-title":"Br J Rheumatol"},{"key":"key-10.4103\/0378-6323.221316-68","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.221316-69","first-page":"CD000956","article-title":"Prazosin for Raynaud's phenomenon in progressive systemic sclerosis","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0378-6323.221316-70","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.apmr.2011.01.022","article-title":"Effectiveness of interventions for secondary Raynaud's phenomenon: A systematic review","author":"Huisstede","year":"2011","journal-title":"Arch Phys Med Rehabil"},{"key":"key-10.4103\/0378-6323.221316-71","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jaad.2005.07.021","article-title":"Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol","author":"Craige","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-72","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/00016348509157025","article-title":"Clonidine in the treatment of menopausal flushing.A review of clinical studies","author":"Hammar","year":"1985","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"key":"key-10.4103\/0378-6323.221316-73","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0022-5347(17)40081-4","article-title":"Treatment of post-orchiectomy hot flashes with transdermal administration of clonidine","author":"Parra","year":"1990","journal-title":"J Urol"},{"key":"key-10.4103\/0378-6323.221316-74","first-page":"687","article-title":"Rilmenidine in rosacea: A double-blind study versus placebo","author":"Grosshans","year":"1997","journal-title":"Ann Dermatol Venereol"},{"key":"key-10.4103\/0378-6323.221316-75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/archderm.1982.01650140041017","article-title":"Blockade of carcinoid flush with cimetidine and clonidine","author":"Wilkin","year":"1982","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0378-6323.221316-76","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0002-9149(68)90142-2","article-title":"The carcinoid syndrome","author":"Grahame-Smith","year":"1968","journal-title":"Am J Cardiol"},{"key":"key-10.4103\/0378-6323.221316-77","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0190-9622(89)70022-0","article-title":"Effect of nadolol on flushing reactions in rosacea","author":"Wilkin","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-78","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2012.04.017","article-title":"Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective \u00df-adrenergic blocker","author":"Hsu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-79","first-page":"650","article-title":", Jackson M, Moore A, Jarratt M, Jones T, Meadows K, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0","author":"Fowler","year":"2013","journal-title":""},{"key":"key-10.4103\/0378-6323.221316-80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.BCR.0000105097.36706.5D","article-title":"Combination of surgery and intralesional verapamil injection in the treatment of the keloid","author":"Copcu","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"key-10.4103\/0378-6323.221316-81","first-page":"37","article-title":"Comparison of the mechanisms of intralesional steroid, interferon or verapamil injection in the treatment of proliferative scars","author":"Xu","year":"2009","journal-title":"Zhonghua Zheng Xing Wai Ke Za Zhi"},{"key":"key-10.4103\/0378-6323.221316-82","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00000637-199608000-00008","article-title":"Treatment of earlobe keloids with surgery plus adjuvant intralesional verapamil and pressure earrings","author":"Lawrence","year":"1996","journal-title":"Ann Plast Surg"},{"key":"key-10.4103\/0378-6323.221316-83","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4103\/0378-6323.42899","article-title":"Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids","author":"Margaret","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.221316-84","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.burns.2013.09.029","article-title":"Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids","author":"Ahuja","year":"2014","journal-title":"Burns"},{"key":"key-10.4103\/0378-6323.221316-85","first-page":"267","article-title":"The treatment of chilblains with nifedipine: The results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial","author":"Rustin","year":"1989","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.221316-86","first-page":"209","article-title":"Diltiazem vs.nifedipine in chilblains: A clinical trial","author":"Patra","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.221316-87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2010.08.039","article-title":"Calcinosis cutis: Part II.Treatment options","author":"Reiter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.221316-88","first-page":"102","article-title":"Regression of cutis calcinosis with diltiazem in adult dermatomyositis","author":"Abdallah-Lotf","year":"2005","journal-title":"Eur J Dermatol"},{"key":"key-10.4103\/0378-6323.221316-89","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1365-2133.2001.04153.x","article-title":"An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem","author":"Ichiki","year":"2001","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.221316-90","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/rheumatology\/39.3.333","article-title":"Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy","author":"Vinen","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"key-10.4103\/0378-6323.221316-91","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/ard.57.4.252","article-title":"Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis.Does diltiazem induce its regression?","author":"Vayssairat","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0378-6323.221316-92","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00105-013-2597-y","article-title":"Spironolactone in dermatological treatment.On and off label indications","author":"Salavastru","year":"2013","journal-title":"Hautarzt"},{"key":"key-10.4103\/0378-6323.221316-93","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.det.2015.11.008","article-title":"Top ten list of clinical pearls in the treatment of acne vulgaris","author":"Layton","year":"2016","journal-title":"Dermatol Clin"},{"key":"key-10.4103\/0378-6323.221316-94","first-page":"CD000194","article-title":"Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne","author":"Brown","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0378-6323.221316-95","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ajd.12362","article-title":"A case series of 20 women with hidradenitis suppurativa treated with spironolactone","author":"Lee","year":"2015","journal-title":"Australas J Dermatol"},{"key":"key-10.4103\/0378-6323.221316-96","doi-asserted-by":"crossref","first-page":"e16319","DOI":"10.1371\/journal.pone.0016319","article-title":"HNF4alpha dysfunction as a molecular rational for cyclosporine induced hypertension","author":"Niehof","year":"2011","journal-title":"PLoS One"},{"key":"key-10.4103\/0378-6323.221316-97","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2133.1994.tb02935.x","article-title":"Efficacy and safety of oral cyclosporin A (CyA;Sandimmun) for long-term treatment of chronic severe plaque psoriasis","author":"Laburte","year":"1994","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.221316-98","first-page":"CD007893","article-title":"Effect of cyclosporine on blood pressure","author":"Robert","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0378-6323.221316-99","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0025-6196(12)65772-3","article-title":"Cyclosporine-induced hypertension after transplantation","author":"Textor","year":"1994","journal-title":"Mayo Clin Proc"},{"key":"key-10.4103\/0378-6323.221316-100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2165\/00002018-199920050-00004","article-title":"Cyclosporin-induced hypertension: Incidence, pathogenesis and management","author":"Taler","year":"1999","journal-title":"Drug Saf"},{"key":"key-10.4103\/0378-6323.221316-101","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1096\/fj.05-4188com","article-title":"Beta2-adrenergic receptor activation delays wound healing","author":"Pullar","year":"2006","journal-title":"FASEB J"},{"key":"key-10.4103\/0378-6323.221316-102","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1440-1681.2006.04383.x","article-title":"Blockade of beta1- and beta2-adrenoceptors delays wound contraction and re-epithelialization in rats","author":"Souza","year":"2006","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"key-10.4103\/0378-6323.221316-103","first-page":"1013","article-title":"Efficacy of propranolol in wound healing for hospitalized burn patients","author":"Mohammadi","year":"2009","journal-title":"J Burn Care Res"},{"key":"key-10.4103\/0378-6323.221316-104","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jamadermatol.2013.7135","article-title":"Topical timolol for recalcitrant wounds","author":"Braun","year":"2013","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/0378-6323.221316-105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1524-4725.2011.02200.x","article-title":"Topical timolol for a refractory wound","author":"Tang","year":"2012","journal-title":"Dermatol Surg"},{"key":"key-10.4103\/0378-6323.221316-106","first-page":"1141","article-title":"Increased calcium levels alter cellular and molecular events in wound healing","author":"Sank","year":"1989","journal-title":"Surgery"},{"key":"key-10.4103\/0378-6323.221316-107","first-page":"294","article-title":"Effect of nifedipine and amlodipine on dead space wound healing in rats","author":"Bhaskar","year":"2005","journal-title":"Indian J Exp Biol"},{"key":"key-10.4103\/0378-6323.221316-108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijpharm.2011.11.021","article-title":"Biopolymeric nifedipine powder for acceleration of wound healing","author":"Samy","year":"2012","journal-title":"Int J Pharm"},{"key":"key-10.4103\/0378-6323.221316-109","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jss.2011.02.039","article-title":"Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats","author":"Bagheri","year":"2011","journal-title":"J Surg Res"},{"key":"key-10.4103\/0378-6323.221316-110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1172\/JCI16645","article-title":"Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth","author":"Egami","year":"2003","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0378-6323.221316-111","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5414\/CNP73439","article-title":"Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients","author":"Moscarelli","year":"2010","journal-title":"Clin Nephrol"},{"key":"key-10.4103\/0378-6323.221316-112","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/jid.2013.35","article-title":"Predictors of squamous cell carcinoma in high-risk patients in the VATTC trial","author":"Xiong","year":"2013","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/0378-6323.221316-113","first-page":"1196","article-title":"Effect of \u00df-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death","author":"De","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"key-10.4103\/0378-6323.221316-114","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.canep.2009.10.005","article-title":"Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","author":"Koomen","year":"2009","journal-title":"Cancer Epidemiol"},{"key":"key-10.4103\/0378-6323.221316-115","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3923\/pjbs.2011.821.830","article-title":"AT1 receptors activation enhances the expression of MMP-2, MMP-13 and VEGF but not MMP-9 in B16F10 melanoma cells","author":"Akhavan","year":"2011","journal-title":"Pak J Biol Sci"},{"key":"key-10.4103\/0378-6323.221316-116","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00280-009-1136-0","article-title":"Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma","author":"Otake","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"key-10.4103\/0378-6323.221316-117","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jdv.12921","article-title":"Use of antihypertensive drugs and risk of skin cancer","author":"Schmidt","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0378-6323.221316-118","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s11095-011-0524-4","article-title":"Development of lidocaine-coated microneedle product for rapid, safe, and prolonged local analgesic action","author":"Zhang","year":"2012","journal-title":"Pharm Res"},{"key":"key-10.4103\/0378-6323.221316-119","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2012.09.041","article-title":"Adjuvants to prolong the local anesthetic effects of coated microneedle products","author":"Zhang","year":"2012","journal-title":"Int J Pharm"},{"key":"key-10.4103\/0378-6323.221316-120","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neulet.2011.04.021","article-title":"Clonidine as adjuvant for oxybuprocaine, bupivacaine or dextrorphan has a significant peripheral action in intensifying and prolonging analgesia in response to local dorsal cutaneous noxious pinprick in rats","author":"Chen","year":"2011","journal-title":"Neurosci Lett"},{"key":"key-10.4103\/0378-6323.221316-121","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neulet.2012.07.036","article-title":"Propranolol elicits cutaneous analgesia against skin nociceptive stimuli in rats","author":"Chen","year":"2012","journal-title":"Neurosci Lett"},{"key":"key-10.4103\/0378-6323.221316-122","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/jid.2015.44","article-title":"Topical mineralocorticoid receptor blockade limits glucocorticoid-induced epidermal atrophy in human skin","author":"Maubec","year":"2015","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/0378-6323.221316-123","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.jid.2016.05.101","article-title":"Re-epithelialization of pathological cutaneous wounds is improved by local mineralocorticoid receptor antagonism","author":"Nguyen","year":"2016","journal-title":"J Invest Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T10:42:17Z","timestamp":1611916937000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/antihypertensives-in-dermatology-part-i-uses-of-antihypertensives-in-dermatology\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"alternative-id":["221316"],"URL":"https:\/\/doi.org\/10.4103\/ijdvl.ijdvl_991_16","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}